Moreover, previous studies demonstrated that the combination of tumor immunotherapy with IL-12 and TNF-α may be more effective to mouse melanoma (33), and heparan sulfate causes the release of TNF-α and IL-12, and induces cytotoxic capability in peritoneal macrophages (34). This evidence concerns the gene TNF and neoplasm.